Skip to main content

Advertisement

SpringerLink
Log in

The impact of evidence-based medicine on diabetes therapy

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.

  2. Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004, 291:335–342.

    Article  PubMed  CAS  Google Scholar 

  3. Mogul HR, Rau J, Weinstein BI, et al.: New perspectives on diagnosis and treatment of obesity. Heart Dis 1999, 1:295-304.

    PubMed  CAS  Google Scholar 

  4. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.

    Article  PubMed  CAS  Google Scholar 

  5. Standards of Medical Care in Diabetes [no authors listed]. Diabetes Care 2005, 28:S4-S36.

  6. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort [no authors listed]. Diabetes Care 1999, 22:99-111.

  7. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Groupia: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002, 287:2563–2569.

    Article  Google Scholar 

  8. Turner RC: The U.K. Prospective Diabetes Study. A review. Diabetes Care 1998, 21(suppl 3):C35-C38.

    PubMed  Google Scholar 

  9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837-853.

  10. Fong DS, Ferris FL 3rd, Davis MD, Chew EY: Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol 1999, 127:137–141.

    Article  PubMed  CAS  Google Scholar 

  11. Hunsicker LG, Atkins RC, Lewis JB, et al.: Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int Suppl 2004, (92):S99-S101.

    Article  PubMed  CAS  Google Scholar 

  12. Rodby RA, Rohde RD, Clarke WR, et al.: The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant 2000, 15:487–497.

    Article  PubMed  CAS  Google Scholar 

  13. Breyer JA, Bain RP, Evans JK, et al.: Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 1996, 50:1651–1658.

    Article  PubMed  CAS  Google Scholar 

  14. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group [no authors listed]. Diabetologia 1996, 39:587-593.

  15. Diagnosis and Classification of Diabetes Mellitus [no authors listed]. Diabetes Care 2005, 28:S37-S42.

  16. Nathan DM: Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002, 347:1342–1349.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Endocrinology Branch, NIDDK, National Institutes of Health, 9000 Rockville Pike, Building 10 CRC Room 5W-5848, 20892-1770, Bethesda, MD, USA

    Phillip Gorden MD

Authors
  1. Phillip Gorden MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carla Musso MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gorden, P., Musso, C. The impact of evidence-based medicine on diabetes therapy. Curr Diab Rep 5, 157–159 (2005). https://doi.org/10.1007/s11892-005-0001-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-005-0001-8

Keywords

Search

Navigation